Feasibility and Safety of Home Blood Count Measurement and Transfusions by Systematically Educated Patients With Acute Myeloid Leukemia

What this Trial Is About

Researchers are studying the feasibility, safety, and complication rates of patients with newly diagnosed Acute Myeloid Leukemia (AML) measuring their own complete blood counts (CBC) and administering blood and platelet transfusions at home. This single-arm feasibility study aims to explore how well patients can monitor vital signs like blood pressure, pulse rate, oxygen saturation, and temperature before and after transfusions. The study also evaluates the potential health economic benefits, such as reducing the need for nurse-driven services during intensive chemotherapy treatment. Participants receive training and certification to perform CBC measurements using the Hemoscreen instrument, self-administer transfusions at home, and monitor vital signs. They learn to draw blood from their central venous catheter and manage medications like antihistamines, acetaminophen, corticosteroids, and epinephrine under healthcare guidance. Although patients perform many tasks independently at home, they will still attend the hospital once weekly for clinical evaluations and transfusions, and have access to nursing support whenever needed. Throughout the study, patients' technical performance using the Hemoscreen device, ability to self-administer transfusions, and accuracy in monitoring vital signs are continuously recorded for up to 12 weeks. Researchers track any transfusion reactions, adverse events, extra healthcare visits, and hospital admissions. They also assess changes in quality of life and patient empowerment over the study period. This detailed monitoring helps evaluate both the safety and practicality of home-based self-care during intensive AML treatment.

Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia